PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › CBL-514

Drugs in development · updated 30 October 2026

CBL-514: clinical trials and development status

Development codeNot approved in the USNo EMA authorisationEstimated launch Sep 2028 – Jul 2029 (Phuturdex estimate)

As of 30 October 2026 CBL-514 is in 5 active clinical trials (recruiting or ongoing, phases I–III) for 0 diseases. The most advanced phase is III.

5Active trials
IIIMost advanced phase
0Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow CBL-514 and get an email at every change or safety alert.

Sign in free →

Everything on CBL-514

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch